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ABSTRACT: 
To evaluate the changes in haematologic indices in patients with pulmonary tuberculosis (PTB) with or without 
Human Immune Deficiency Virus (HIV) co-infection in South Eastern Nigeria. The study population included 
116 subjects (60 = males; 56 = females), recruited from 2 study centers: mile 4 Hospital Abakaliki Ebonyi State 
and Nnamdi Azikiwe University, Teaching  Hospital Nnewi, Anambra State, both in Nigeria. PTB + HIV (n = 
20); PTB infection ( n = 27) and HIV sereopositive (n = 28). The PTB and HIV negative; control subjects were 
41 (n = 41). Blood samples collected from subjects in Ethylene diamine tetra acetic acid (EDTA) container were 
used for the analysis of the Haemtological cells count,  packed cell volume (PCV) and Haemoglobin estimation 
using routine methods as described (Dacie and Lewis, 1984). HIV screening was done with Stat pak kit and 
confirmatory test by Western blot method. Erythrocyte sedimentation rate (ESR) was by Westergren method. 
Haemoglobin estimation (Hb), packed cell volume (PCV) values were significantly lower in patients with PTB 
(11.27±1.62 g/dl, 0.35±0.04 l/l) compared with control values (13.67±1.46 g/dl 0.41 ± 0.05 l/l) (p < 0.05). 
Patients with HIV seropositive showed significantly low PCV values of (0.36 ± 0.04 l/l) compared with the 
control subjects (0.41 ± 0.05 l/l) (p < 0.05). PTB patients showed higher TWBC counts (6062.5 ± 1481.83109/l) 
when compared those with HIV infection (3841.38±735.58 x 109/l) as well as normal control value 
(4363.64±551.66 x 109/l) (p < 0.05). Male and female values compared in this work showed no significant 
difference (p > 0.05). The results showed that the effect of PTB and HIV infection have caused some 
haematological deregulation. It also showed that sex has little or no effect on the studied parameters. 
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INTRODUCTION:The past few years have witnessed a word wide resurgence of pulmonary tuberculosis 
(PTB) due to Human Immuno Deficiency Virus (HIV co-infection (WHO, 2005). Tuberculosis is an old disease 
of man and one of the most widespread and persistent disease of this century (1910 – 2013) (WHO. 2005). Some 
reports over the past several years have indicated that while tuberculosis problem is on the wane in most 
developed countries, the disease still ranks as a major health problem in the developing countries; in general and 
in Africa in particular (WHO, 1982, 2008). It has been reported that Human Immunodeficiency Virus (HIV) 
pandemic has caused an increase in the number of patients with PTB particularly in African and South East Asia 
(Raviglone et at, 1995). A variety of factors have been identified as being predictive of a greater risk of death in 
PTB patients for example, inadequate treatment, and late diagnosis of the disease, multidrug resistant, 
tuberculosis and HIV infection as well as advanced age (Connoly et at, 1999). Extra pulmonary tuberculosis 
(EPTB) is also on the rise with approximately ten percent (10%) of the cases involving the bone and the joints 
(Putong et al, 2002). Patients with PTB may present with a variety of rheumatic symptoms and signs even 
without evidence of direct muscoskeletal or local involvement PTB and systemic lupus erthematosus (SLE) 
share many symtoms such as fever, myalgias, arthalgia/arthritis, rash and multi organ involvement (Watts et al, 
1996). 
Nigeria is a country with high incidence of tuberculosis. A recent report on the incidence in Nigeria shows there 
is a prevalence rate of 19.5%. (Jemikalajah et al, 2009). Hence, there is need to review modalities of the 
implementation of various components involved in control of TB. The aim of this study is to establish the 
importance of haematologic parameters such as Hb, PCV, ESR, WBC, platelet count, Differential white cell 
count in monitoring and management of PTB with or without HIV-co-infection. 
MATERIALS AND METHODS: This study was conducted at the chest clinics of Mile 4 Abakaliki, Ebonyi 
State and Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra State, both in Nigeria. Patients who 
have tested positive for Mycobacterium tuberculosis, by Ziehl-Neelson (Z-N) stain of the sputum were recruited. 
A total number of 116 subjects were recruited, (60 = males, 56 = females) from the two treatment centers: Mile 4 
Hospital Abakaliki (47) Nnamdi Azikiwe University Teaching Hospital, Nnewi Campus (69). These comprised, 
20 patients with pulmonary tuberculosis and HIV – co-infection (PTB + HIV), (males 10, female = 10), 27 
patients with pulmonary tuberculosis (PTB) without HIV co-infection (PTB); (males = 15, females = 12), 28 
patients with HIV seropositive (males = 14, females = 14), 41 apparently healthy control subjects which 
comprises staff and students of the two institutions, (males = 21 females = 20). 
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The following haematologic parameters were carried out on EDTA anticoagulated blood samples collected from 
the subjects: Haemoglobin (Hb), Packed Cell Volume (PCV), Total white blood cell count (TWBC), Platelet 
count (PLT), Erythrocyte sedimentation rate (ESR), Differential white bleed cell count;  neutrophils (neut), 
lymphocytes (lymph), eosinophils (eosino), monocytes (mono) and basophils (baso). 
Haemoglobin determination was done by cyanmethaemoglobin method, whereby haemoglobin was converted to 
haemoglobin cyanide (HICN) and colour change.  
Blood samples collected in EDTA container were used for the analysis of the Haematological cells count and 
Haemoglobin estimation using standard method as described in (Dacie and Lewis 1984). HIV screening and 
confirmatory tests were done using Stat Pak and western blot kits respectively. Stat Pak Assay-Chembio 
Diagnostic system USA, Western Blot technique for confirmation using Qualicode TM HIV kit (Immunetics, 
Boston USA) 
 TEST METHODS: Haemoglobin determination was done cymethaemoglobin method. The packed cell volume 
was determined using the microhaematocrit standard method whereby EDTA blood was separated in, 4 layers 
(red cells, platelets, white blood cells and plasma). The red cell layer was read with a microhaematocrit reader 
and calculated as percentage of the whole blood. The total white blood cell count was done using Turk’s solution 
as the diluents and was counted manually using haemacytometer (Improved Neubauer counting chamber). The 
erythrocyte sedimentation rate (ESR) was done by Westergren method. The differential white blood cell count 
was done using the manual method. The thin film stained by the Romanowsky method, was examined using oil 
immersion objective lens (X100mm) while the proportion of the white cell types were expressed in percentage. 
All the tests procedures above were as described by Dacie and Lewis (1984). 
STATISTICAL ANALYSIS: Data obtained were analyzed using student t-test and ANOVA. The variables 
were expressed in mean ± standard deviation (±SD) then compared. The significant difference was regarded as P 
< 0.05 
 
RESULTS: Table I shows the mean ± SD comparison of haematologic changes in PTB, PTB + HIV, HIV 
seropositive patients and normal control subjects. The between comparisons among the four group: mean ± SD 
Hb g/dl for PTB is 11.60±1.96, PTB + HIV = 11.29±1.6, HIV seropositive patients = 11.50±1.15, Normal 
control 13.67 ± 1.46. This showed no statistical difference (F = 1.059; p > 0.05). However, mean ± SD PCV l/l 
for PTB; .35 ± .07, PTB + HIV; 0.35 ± 0.04, HIV seropositive; 0.36 ± 0.05, and normal control; 0.41 ± 0.05 
showed statistical significant difference among the four groups (f = 5.07, p < 0.05). The mean ± SD ESR mm/hr 
compared among PTB (68.63 ± 31.81), PTB + HIV (75.00 ± 43.59), HIV seropositive patients (43.14 ± 42.37), 
and control  showed significant difference (F = 3.35, p < 0.05). Moreover, mean ± SD WBC x 109g/l in PTB 
(6062.5 ± 1481.83), PTB + HIV (4422.22 ± 1851.88), HIV seropositive (3841.38 ± 735.58) and normal control 
(4363.64 ± 551 .66) compared showed significant difference. 
Also, the mean ± SD Neutrophil % in PTB (50.63 ± 17.95); PTB + HIV (38.89 ± 17.90), HIV seropositive 
(37.93 ± 15.54) and normal control (33.41 ± 8.99), the mean ± SD Lymphocyte % in PTB (40.88 ± 19.08), PTB 
+ HIV (56.33 ± 17.90), HIV seropositive (55.28 ± 16.15) and normal control (60.77 ± 8.16) respectively 
compared showed statistical significant difference. See table 1. However, the mean ± SD monocyte in PTB 
(3.21±1.97); PTB + HIV (3.75±2.49), HIV seropositive (4.50 ± 2.81) and control (3.57 ± 1.63) when compared 
were not statistically significant (F = 1.12; p>0.05). The mean ± SD compared within the groups for Hb. g/dl in 
PTB and control showed statistical significant difference (p < 0.05). However, mean ± SD of the following 
groups PTB and PTB + HIV, HIV seropositive and control compared applying post Hock, showed no statistical 
significant difference (p > 0.05). 
The mean ± SD compared within the groups applying post Hock for PCV l/l showed significant statistical 
difference (p < 0.05) between PTB and control, HIV seropositive and control, PTB + HIV and control. However, 
the mean ± SD post Hock comparison between PTB and PTB + HIV, HIV seropositive and PTB + HIV and PTB 
and PTB + HIV respectively, showed no significant statistical difference (p > 0.05). 
Also, the mean  ± SD post Hock comparison of WBC x 109g/dl  showed that PTB and HIV, PTB and normal 
control and HIV seropositive and normal control were statistically significant (p < 0.05). The statistical 
comparison between PTB and PTB + HIV, HIV seropositive and PTB + HI, then PTB + HIV and normal control 
groups in WBC x 109g/dl show statistically no significant difference (p > 0.05).  
The mean ± SD neutrophil % compared between the following: PTB and HIV, PTB and PTB + HIV, HIV 
seropositive and normal control then PTB + HIV and normal control were in each case, not significantly 
different (p > 0.05). Also, the mean ± SD neutrophil % compared by post Hock analysis between PTB and 
normal control showed statistical significant difference (p < 0.05). 
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The mean ± SD Lymphocyte % compared between PTB and HIV, PTB and PTB + HIV, HIV seropositive and 
PTB + HIV, HIV seropositive and control, then PTB + HIV and control show no significant difference (p > 
0.05). However, mean ± SD comparison of lymphocyte % between PTB and normal control show statistical 
significant difference (p < 0.05). Mean ± SD lymphocyte % comparison within all the groups: PTB and HIV 
seropositive, PTB and PTB + HIV, PTB and normal control HIV seropositive and PTB + HIV, HIV seropositive 
and normal control showed no significant difference (p > 0.05 in each case). (See table 1). 
The mean ± SD platelet count (X109g/dl   ) values in PTB (223, 166.67 ± 56, 056 – 39), HIV seropositive 
(179,666.67 ± 39831.381), PTB + HIV (191,000.00 ± 63,493.53) and control (178, 545.45 ± 34, 617.26), were 
compared using ANOVA and showed significant mean difference (F = 4.81, p < 0.05). The mean ± SD 
comparison of platelets between PTB and HIV seropositives, showed higher significant value in PTB (p<0.05). 
Also the mean ±SD platelets count showed higher significant value in PTB compared with the controls (p<0.05). 
However, the mean ± SD platelet count compared between PTB  and PTB + HIV, HIV seropositive and PTB + 
HIV also between HIV seropositive and control and PTB + HIV and control showed no significant difference in 
values (p > 0,05) in each case. 
The mean ± SD ESR mm/hr values in PTB (75.54 ± 36.71), HIV seropositive (46.89 ± 41.65); PTB + HIV 
(112.75 ± 32.07), and control subjects (11.18 ± 9.75) compared using ANOVA presented statistically significant 
difference (F = 24, 13; p < 0.05). Mean ± SD comparison of values in ESR using tests showed that PTB, HIV 
seropositve and PTB + HIV, ESR mm/hr values were significantly higher than the values of ESR mm/hr in the 
control subjects (p < 0.05) in each case. Also, PTB compared with HIV seropositive ESR mm/hr values showed 
higher significant difference (p < 0.05). Also the comparison of the PTB + HIV compared with PTB showed 
statistically significant difference (p < 0.05). 
The mean ±SD for MCHC values in PTB (32.64 ± 1.90), HIV seropositives (32.84 ± 1.26), PTB + HIV (33.16 ± 
1.95) and control (33.40 ± 1.32) compared showed no significant difference (F = 2.03; p = 0.11). Moreover, 
further inter - comparison of values in parameter (MCHC) in PTB and HIV seropositive PTB and PTB + HIV, 
PTB and control showed similar mean values ( p > 0.05) in each case. 
Table 2, Compared the mean ± SD, Haematological changes in different groups PTB, HIV seropositive, PTB + 
HIV and normal control, between male and female (in each case) using student’s t test. 
The mean ± SD Hb g/dl in PTB compared between male (11.76 ± 1.95) and female (11.06 ± 1.60) showed no 
statistical significant difference (p > 0.05). Also, mean ± SD PCV l/l compared between male (0.35 ± .07) and 
female (0.34 ± 0.04) showed no significant difference (p > 0.05). Mean ± SD WBC x 109/l.  ESR mm/hr, in PTB 
compared between male (6.25 ± 1.39, 87.67 ± 40.13) respectively and female (4.76 ± 1.06; 64.70 ± 31.00) 
respectively were both not significantly different in values (p > 0.05). Moreover, the mean ± SD neutrophil % 
and lymphocyte % in PTB male and female patients compared showed no statistical significant difference (p > 
0.05 in each case). 
The mean ± SD Hb g/dl; PCV l/l, platelet x 109/l, WBC x 109/l, ESR mm/hr, Neutrophil % and Lymphocyte %, 
in PTB + HIV infected males and females compared (in each case), were statistically similar in value ( p > 0.05). 
Also mean ± SD Hb g/dl; PCV l/l, WBC x 109/l, ESR mm/hr, Neutrophil % and Lymphocyte % values, 
compared between control male and female (in each case) resulted in statistically no significant difference (p > 
0.05); On the other hand, mean ± SD, platelet count x 109/l in PTB male (225.54 ± 54.4) compared with female 
(125.6 ± 38.47) showed higher significant difference (p < 0.05). However, mean ± SD monocyte in PTB, 
compared between male (1.82 ± 1.40) and female (3.91 ± 2.43) show significantly lower difference (p < 0.05). 
DISCUSSION: There was a significantly lower haemoglobin level in PTB patients with and without HIV co-
infection in this study. This may be due to decreased erythrocyte lifespan, impaired marrow response or impaired 
flow of iron (fe) from macrophages to the plasma in iron (fe) cycle metabolism. This decrease in haemoglobin 
may also be due to a non-immune mechanism that develops secondary to granulomatous infiltration of the bone 
marrow. This finding is in agreement with those of (Das et al 2003; Lawson et al 2008; Mugusi et at 2009; and 
Ursavas et al 2010); who suggested a mild to moderate anaemia that frequently accompanied infections, 
inflammatory and neoplastic diseases. The anaemia may reflect reticuloendothelia iron block by disease entity 
and in HIV disease; partly due to suppression of erythropoiesis by cell to cell interaction (Lemoha et al 2004; 
Mugasi et al 2009 and Ursavas et at, 2010). 
The mean ESR in PTB and PTB + HIV patients was significantly high when compared with that of control 
subjects. The reason may be due to alterations in the plasma proteins as may be the case in different entities 
(Ursavas et al, 2010). Since the erythrocyte sedimentation rate is a non-specific reaction which may be compared 
with the body temperature, pulse rate and the leukocyte count, it is a measure of the inflammatory response or 
reaction in a disease entity.    
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Hence an accelerated erythrocyte sedimentation rate (ESR) is seen in patients with PTB and PTB + HIV and 
HIV seropositive patients when compared with control.   
So an accelerated erythrocyte sedimentation rate (ESR) may serve as a guide to the progress of disease that has 
already been recognized and this being particularly true in regard to pulmonary tuberculosis (Bozoky et al, 1999 
and Ursavas et al, 2010). 
The total white blood cell count (WBC) of patients with PTB + HIV and PTB were significantly higher than 
those of the control subjects in this study. The reason for these alterations in the blood leukocyte concentration 
which in this case was due to neutrophilia is an indication of recurrent continuous inflammatory response. This 
will usually change to lymphocytosis during chronic inflammatory response, the patients used for this study were 
those with active tuberculosis and the findings were in agreement with those of (Jadoon et al 2004 and Ursavas 
et al, 2000). The total WBC in patients with HIV seropositive in this study showed mild leucopenia. This 
observed difference, might be due to the causative agent, HIV, a lentivirus, when compared with that of PTB, 
caused by Mycobacterium tuberculosis. Another reason, for the leucopenia in HIV infection might be due to 
decrease bone marrow production of granulocyte progenitor cells (CFUGM), colony forming unit granulocyte – 
monocyte from the bone marrow of patients with HIV infection (Costello et al, 1999). 
The result also showed a significant increase in monocyte count in patients with PTB and PTB + HIV. The 
monocyte, a known phagocytic cell is expected to be increased in active tuberculosis infection. Hence, this 
finding is in agreement with of previous authors (Bozoky et al, 1997). 
There was no significant difference in lymphocyte count of patients with PTB and PTB + HIV, when compared 
in each case with control. This is not in agreement with previous report by Bozoky et al, (1997) who reported 
mild lymphocytosis in PTB with or without HIV co-infection. The location where this study was done may have 
contributed to this different observation. 
The MCHC result in this study showed low normal results; hence there is no significant difference between the 
PTB, HIV seropositive and PTB + HIV with the normal control results. Although, anaemia is recorded for the 
patients but the type is anaemia of chronic disorder, hence, normocytic – normochronic. This is in agreement 
with previous report of Treacy et al (1984); who reported a mild anaemia in HIV/AIDS patients. It does not 
agree with the report of severe anaemia with erythroid hypoplasia in HIV patients with disseminated 
mycobacterium avium intracellular (MAI) infection  (Gardener et al 1987). 
The platelets result in this study, showed significant difference between the groups. The count in PTB is 
significantly higher than those of HIV seropositive, normal control and PTB + HIV. The mean ± SD platelet 
count showed no significant difference in values between PTB + HIV, HIV seropositive and control groups. This 
is in agreement with previous report by Pust et al 1974, which showed there was mild thrombocytosis in 
tuberculosis. The result is also in agreement with previous report by Costello et al (1999) which showed there is 
mild thrombocytopenia in male and female patients with HIV. Some authors have reported presence of auto-
antibody complexes as being responsible for the mild decreased platelet count in HIV infection (Mugusi et al, 
2009). 
The Haematologic changes in PTB + HIV, PTB and HIV seropositive patients showed varied pictures due to the 
stage of the infection and the causative agents. Mycobacterium tuberculosis and Human Immune deficiency 
virus.   
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Table 1: HAEMATOLOGICAL CHANGES IN PTB, HIV, PTB + HIV AND NORMAL CONTROL 
SUBJECTS.   
 
SUBJECT Hb 
g/dl 
PCV 
l/l 
ESR 
mm/hr 
WBC 
x109/l 
Platelet 
x109/l 
Neut. 
% 
Lymph 
% 
Mono 
% 
MCHC 
          
1, PTB 
(n=32 
11.60 
± 1.96 
0.35 ± 
0.07 
75.54 ± 
36.71 
6062.5 ± 
1481.83 
223166.67 ± 
56056.39  
50.63 
± 
17.95 
40.88 ± 
19.08 
3.21 ± 
1.97 
32.64 ± 
1.90 
2, HIV 
(n=58) 
 
11.51 
± 2.15 
0.36 ± 
0.05 
46.89 ± 
41.65 
3841.38 
± 735.58 
179666.67 ± 
39831.38 
37.93 
± 
15.54 
55.28 ± 
16.15 
4.50 ± 
2.81 
32.84 ± 
1.26 
3, 
PTB+HIV 
(n=20) 
 
11.27 
± 1.62 
0.35 ± 
0.04 
112.75 
± 32.07 
4422.22 
± 
1851.88 
191000.00 ± 
63,493.53 
38.89 
± 
17.95 
56.33 ± 
17.90 
3.75 ± 
2.49 
33.16 ± 
1.95 
4, Control 
(n=40) 
 
13.67 
± 1.46 
0.41 ± 
0.05 
11.18 ± 
9.75 
4363.64 
± 551.66 
178545.45 ± 
34617.26 
53.41 
± 8.99 
60.77 ± 
8.16 
3.57 ± 
1.63 
33.40 ± 
1.32 
F (p) Value 1.059 
0.37 
5.07 
0.003 
24.13 
0.043 
15.25 
0.00 
4.81 
0.004 
4.34 
0.007 
5.54 
0.002 
1.12 
0.35 
2.03 
(0.11) 
1 vs. 2 p 
Value 
0.41 0.96 0.06 0.00 0.02 0.11 0.074 0.36 0.38 
1vs. 3 p 
Value  
0.97 0.99 0.07 0.15 0.60 0.42 0.22 0.95 0.91 
1 vs. 4    “ 0.007 0.044 0.00 0.002 0.01 0.01 0.005 0.94 0.06 
2 vs. 3    “  0.37 0.86 0.00 0.80 1.96 1.0 1.0 0.89 0.81 
2 vs. 4    “ 0.74 0.007 0.00 0.33 1.00 0.56 0.40 0.52 0.92 
3 vs. 4    “         
0.009 
0.017 0.00 1.0 0.95 0.82 0.89 0.97 0.36 
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Table 2: Haematologic Changes in Different Groups: PTB, PTB + HIV, HIV Seropositive and Normal 
Control compared between sexes (male and female) using student’s t tests.                         
S/N SUBJECT Hb 
g/dl 
PCV 
l/l 
WBC 
x109/l  
ESR 
mm/hr 
Mono 
% 
Neut 
% 
Lymph 
% 
Platelets 
x109/l 
          
1 PTB – HIV male  
(n=30) 
11.76 
± 
1.95 
0.35 
± 
0.07 
6.25 ± 
1.39 
87.67 ± 
40.13 
1.82 ± 
1.40 
50.87 
± 
16.66 
41.40 ± 
16.77 
244.33±46.39 
2 PTB – HIV 
female (n=20) 
11.06 
± 
1.60 
0.34 
± 
0.04 
4.76 ± 
1.06 
64.70 ± 
31.00 
3.91 ± 
2.43 
39.70 
± 
19.92 
54.00 ± 
22.39 
233.55±67.16 
3 PTB–HIV 
male/female  
P-value 
0.97 0.99 0.09 0.74 0.03 0.82 0.79 0.69 
4 PTB + HIV male  
(n=10) 
10.36 
± 5.1 
0.33 
± 
0.05 
5.46 ± 
1.24 
131.00 
± 74.20 
1.67 ± 
1.53 
43.00 
± 
21.42 
51.60 ± 
40.85 
164.08±33.07 
5 PTB + HIV 
female (n=6) 
12.80 
± 
0.53 
0.37 
± 
0.02 
4.30 ± 
0.61 
60.00 ± 
34.64 
3.67 ± 
3.06 
30.67 
± 
14.19 
67.00 ± 
12.12 
184.58±42.68 
6 PTB + HIV 
male/female 
0.16 0.85 0.66 0.63 0.32 0.96 0.87 0.19 
7 HIVseropositive 
male 
(n=24) 
13.12 
± 
1.84 
0.39 
± 
0.05 
3.68 ± 
0.60 
32.92 ± 
37.50 
3.42 ± 
2.71 
33.83 
± 
15.41 
60.42 ± 
16.78 
225.40±54.5 
8 HIV seropositive 
female (n=30) 
11.24 
± 
1.54 
0.34 
± 
0.04 
4.0 ± 
0.90 
54.73 ± 
46.44 
3.83 ± 
3.27 
40.67 
± 
16.47 
51.60 ± 
16.10 
125.60±38.47 
9 HIV male/female 
P.Value 
0.14 0.17 0.96 0.87 0.74 0.95 0.86 0.02 
10 Control male 
(n=22) 
14.78 
± 
1.05 
0.43 
± 
0.04 
4.11 ± 
0.45 
7.73 ± 
5.62 
2.64 ± 
1.69 
33.27 
± 7.76 
61.00 ± 
4.45 
169.09±36.61 
11 Control female 
(n=18) 
12.56 
± .83 
0.38 
± .o4 
4.54 ± 
.04 
14.64 ± 
11.91 
4.18 ± 
1.54 
33.54 
± 
10.49 
60.55 ± 
10.95 
188.00±31.30 
12 Control male / 
female 
P Value 
0.001 0.06 .71 .67 0.08 1.00 1.00 0.16 
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